Cite

HARVARD Citation

    Wang, X. et al. (2023). Concerns on Bebtelovimab (LY‐CoV1404) used to neutralize Omicron subvariants. Journal of medical virology. 95 (2), p. n/a. [Online]. 
  
Back to record